Compare AbbVie Inc (ABBV) vs Carvana Co (CVNA) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Carvana (CVNA) trades at $70.85, up 3.73% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue surged 52% year-over-year in Q2 2026 to $7.38 billion, driven by record retail unit growth, though profit margins face pressure. The stock is near its consensus price target of $87.18, with analyst sentiment split between Buy and Hold ratings.

Outlook remains positive due to aggressive scaling and AI-driven cost efficiencies, but risks include high debt levels and competitive threats. Investors should weigh robust growth against valuation concerns, with the current P/E of 37.5 reflecting high expectations. Near-term performance hinges on execution of margin improvement goals.